ProfileGDS5678 / 1444176_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 58% 68% 48% 48% 59% 49% 52% 50% 52% 68% 52% 51% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7089461
GSM967853U87-EV human glioblastoma xenograft - Control 23.4887558
GSM967854U87-EV human glioblastoma xenograft - Control 34.1786668
GSM967855U87-EV human glioblastoma xenograft - Control 43.0708448
GSM967856U87-EV human glioblastoma xenograft - Control 53.092848
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6200259
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.257949
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2425752
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1898550
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.240552
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.113468
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.226452
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2298251
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4602857